Практические Рекомендации По Лекарственному Лечению Рака Яичников, Первичного Рака Брюшины И Рака Маточных Труб

Тюляндин, С. А.; Коломиец, Л. А.; Морхов, К. Ю.; Нечушкина, В. М.; Pokataev, I.; Румянцев, А. А.; Тюляндина, А. С.; Урманчеева, А. Ф.; Хохлова, С. В.

doi:10.18027/2224-5057-2020-10-3s2-10

Cited by 6 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Исследование одобрено этическим комитетом ИМЭиФК Ульяновского государственного университета (протокол № 3 от 15.03.2017). Образцы ткани опухоли получены интраоперационно: у пациенток, получавших адъювантную химиотерапию (АХТ), -до начала химиотерапии, а у пациенток, получавших неоадъювантную химиотерапию (НАХТ), -после трех курсов химиотерапии по схеме ТР (карбоплатин AUC6 + паклитаксел 175 мг/м 3 внутривенно капельно 1 раз в 3 недели) согласно международным и национальным рекомендациям [10]. Хирургическое лечение выполнялось в объеме гистерэктомии с двусторонней сальпингоофорэктомией и оментэктомией.…”

Section: материалы и методыunclassified

Expression of cancer stem cell markers CD44, CD133, and ALDH in a primary tumor before and after platinum-containing chemotherapy in ovarian cancer

Генинг¹,

Антонеева²,

Абакумова³

et al. 2021

Clin. Exp. Morphology

View full text Add to dashboard Cite

Introduction. Ovarian cancer (OC) is characterized by an unfavorable clinical course. Difficulties in the treatment of OC can be due to intratumoral heterogeneity, which includes the presence of stem cells. The aim of this study was to assess the expression of stem markers in the tissue of primary OC before and during chemotherapy of OC in association with the clinical features of the disease. Materials and methods. A retrospective study evaluated tissue samples of the primary tumors of patients (n=28) with stages I–IV epithelial OC obtained before or after 3 courses of chemotherapy. The expression of ALDH, CD44, and CD133 was assessed by immunohistochemistry. Results. In samples of high-grade serous adenocarcinoma, the percentages of cells expressing ALDH (p=0.008), CD44 (p=0.026), and CD133 (p=0.059) were lower than in other subtypes. Tissue samples obtained before treatment showed a higher percentage of cells expressing CD44 (p=0.053) than the ones obtained after neoadjuvant chemotherapy. There was a tendency towards higher expression of CD44 (p=0.056) and ALDH (p=0.074) in stages I–II tumors when compared to that in stages III–IV. In the neoadjuvant chemotherapy group, patients with clinically platinum-sensitive tumors had a higher percentage of CD44+ cells than those with non-platinum-sensitive ones (p=0.038). The number of tumor cells expressing ALDH rose with the increase in CD44+ cells number (R2=0.280, p=0.005). We found a positive correlation between the numbers of CD44+ and CD133+ cells in the tumor parenchyma (r=0.408, p=0.031). Conclusion. Cancer stem cell markers are co-expressed in primary tumor tissue in OC. The expression of stem markers differs depending on the histological subtype and the presence of prior exposure to chemotherapy. Keywords: tumor stem cells, ovarian cancer, chemotherapy, CD44, CD133, ALDH, immunohistochemistry

show abstract

Section: материалы и методыunclassified

Expression of cancer stem cell markers CD44, CD133, and ALDH in a primary tumor before and after platinum-containing chemotherapy in ovarian cancer

Генинг¹,

Антонеева²,

Абакумова³

et al. 2021

Clin. Exp. Morphology

View full text Add to dashboard Cite

show abstract

“…В случае серозного рака низкой степени злокачественности после окончания ХТ возможна поддерживающая эндокринная терапия ингибиторами ароматазы (в стандартных дозах) или тамоксифеном в дозе 20-40 мг/сут в течение 3 лет или до прогрессирования [19].…”

Section: лекарственное лечениеunclassified

“…Заболевание, вызванное SARS-CoV-2, известное как коронавирусная болезнь 2019 г. (COVOD- 19), повлияло на все аспекты жизни во всем мире.…”

Section: Introductionunclassified

Diagnostics and treatment of basic oncogynecological diseases (including those occurring during pregnancy) in the conditions of the COVID-19 pandemic. Educational and Methodological Manual

Protasova¹,

Vandeeva²,

Zazerskaya³

et al. 2020

View full text Add to dashboard Cite

show abstract

“…О роли и месте хирургического лечения при рецидиве РЯ ведутся дискуссии на протяжении последних 30 лет. Химиотерапия (ХТ) в настоящее время является основным методом лечения больных c рецидивом РЯ [4]. Тем не менее все большее число данных подтверждает, что вторичная циторедукция (ВЦ) улучшает продолжительность жизни (ПЖ) у правильно отобранной популяции пациенток, страдающих Стилиди Иван Сократович -акад.…”

Section: Introductionunclassified

Surgical treatment of recurrent ovarian cancer: A review

2021

View full text Add to dashboard Cite

Aim. To analyze the data available in the modern literature on the role of repeated cytoreduction in the complex treatment of relapses ovarian cancer (OC). Materials and methods. Sources were searched in the following systems Clinicaltrials.gov, PubMed, Medline, NCCN, Scopus, Gynecol Oncol, Elibrary. After analyzing the literature review, 31 sources were used, published from January 1989 to December 2020. Results. The main method of treatment relapses of ОС is administration of systemic chemotherapy. The role of surgical treatment has been actively discussed for several decades. According to the available data of retrospective, prospective, randomized trials, performing surgery following chemotherapy had a favorable effect on the long-term results of treatment just in case of achieving complete cytoreduction in comparison with only chemotherapeutic treatment of platinum-sensitive recurrence of ОС. A validated prognostic model helps to perform the selection of suitable patients for surgical treatment, therefore, the correct selection for secondary cytoreduction allows to identify the patients with a high chance of achieving сomplete cytoreduction, which reduces the number of ineffective operations in patients with residual tumors. Conclusion. Complete cytoreduction of all macroscopically detectable recurrent tumor lesions in combination with subsequent systemic chemotherapy leads to an improvement in progression-free survival and life expectancy in a carefully selected group of patients with platinum-sensitive recurrent OC. Secondary cytoreduction in platinum-refractory and platinum-resistant relapses deteriorates the prognosis and doesn't lead to an increase in survival rates. Patient selection is the key point in secondary cytoreductive surgery. The choice of the methodology of selection of patients is in the process of discussion. When planning treatment, all patients with recurrent OC should be discussed at multidisciplinary teams with the participation of specialists in related specialties. Considering a surgical treatment option should be performed it in large centers with extensive experience in the surgical treatment of OC, relapses, performing complex multi-organ resections.

show abstract

Практические Рекомендации По Лекарственному Лечению Рака Яичников, Первичного Рака Брюшины И Рака Маточных Труб

Abstract: .

Cited by 6 publications

References 0 publications

Expression of cancer stem cell markers CD44, CD133, and ALDH in a primary tumor before and after platinum-containing chemotherapy in ovarian cancer

Expression of cancer stem cell markers CD44, CD133, and ALDH in a primary tumor before and after platinum-containing chemotherapy in ovarian cancer

Diagnostics and treatment of basic oncogynecological diseases (including those occurring during pregnancy) in the conditions of the COVID-19 pandemic. Educational and Methodological Manual

Surgical treatment of recurrent ovarian cancer: A review

Contact Info

Product

Resources

About